About Sol-Gel Technologies
Sol-Gel Technologies is a company based in United States founded in 1998 by Alon Seri-Levy and David Avnir. Sol-Gel Technologies has raised $9 million across 8 funding rounds from investors including National Science Foundation. The company has 34 employees as of December 31, 2024. Sol-Gel Technologies has completed 1 acquisition, including Patidegib. Sol-Gel Technologies operates in a competitive market with competitors including Revance Therapeutics, Dermavant, SkinMedica, Hugel and Collplant, among others.
- Headquarter United States
- Employees 34 as on 31 Dec, 2024
- Founders Alon Seri-Levy, David Avnir
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sol-Gel Technologies Ltd.
-
Annual Revenue
$11.54 M (USD)642.47as on Dec 31, 2024
-
Net Profit
-$10.58 M (USD)61.16as on Dec 31, 2024
-
EBITDA
-$11.78 M (USD)59.4as on Dec 31, 2024
-
Total Equity Funding
$9 M (USD)
in 8 rounds
-
Latest Funding Round
$5 M (USD), Post-IPO
Apr 13, 2020
- Investors
-
Employee Count
34
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Sol-Gel Technologies
Sol-Gel Technologies is a publicly listed company on the NASDAQ with ticker symbol SLGL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Sol-Gel Technologies
Unlock access to complete
Funding Insights of Sol-Gel Technologies
Sol-Gel Technologies has successfully raised a total of $9M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $5 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Sol-Gel Technologies
Sol-Gel Technologies has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include National Science Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A government-backed foundation providing seed-stage investments to support small businesses.
|
Locked | Locked | Locked |
Investor details for Sol-Gel Technologies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sol-Gel Technologies
Sol-Gel Technologies has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Patidegib.
Investment portfolio details for Sol-Gel Technologies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Cancer therapy drug development services are provided by Patidegib.
|
Locked | Locked | 0 | Locked |
Complete acquisition details for Sol-Gel Technologies
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Sol-Gel Technologies
Detailed financials for Sol-Gel Technologies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sol-Gel Technologies Comparisons
Peer comparison for Sol-Gel Technologies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sol-Gel Technologies
Sol-Gel Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Dermavant, SkinMedica, Hugel and Collplant, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurotoxin products for aesthetic and therapeutic skin treatments are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory skin diseases are developed.
|
|
| Locked | Locked | Locked |
Skin care products are developed and manufactured by SkinMedica.
|
|
| Locked | Locked | Locked |
Therapeutics in aesthetics are developed, including botulinum toxin products.
|
|
| Locked | Locked | Locked |
Plant-derived collagen is developed for tissue repair and 3D bioprinting.
|
Detailed competitors of Sol-Gel Technologies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sol-Gel Technologies
Complete news archive for Sol-Gel Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sol-Gel Technologies
Sol-Gel Technologies was founded in 1998 and raised its 1st funding round 9 years after it was founded.
Sol-Gel Technologies is headquartered in United States.
Alon Seri-Levy is the current CEO of Sol-Gel Technologies. They have also founded this company.
Sol-Gel Technologies is a funded company, having raised a total of $9M across 8 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Sol-Gel Technologies is 34.
Annual revenue of Sol-Gel Technologies is $11.54M as on Dec 31, 2024.
Sol-Gel is a clinical-stage specialty pharma focused on developing topical dermatological drug products. Its drug pipeline includes VERED (Phase 2), a topical encapsulated benzoyl peroxide cream for the treatment of papulopustular rosacea; TWIN (Phase 2), a non-antibiotic topical cream and SIRS-T (PreclinicalPhase 1), a topical encapsulated tretinoin cream for the treatment of acne vulgaris E-06 (preclinicalphase 1), a cream formulation of a new fixed-dose combination, containing an antifungal agent and a mid-potency steroid for the treatment of symptomatic c(athletes foot). All its products are based on its proprietary microencapsulation delivery system.
Sol-Gel Technologies's top competitors include Revance Therapeutics, Dermavant and Collplant.
Yes, Sol-Gel Technologies is publicly traded on NASDAQ under the ticker symbol SLGL.
Sol-Gel Technologies has made 1 acquisition, including Patidegib.
Sol-Gel Technologies has 1 investor. Key investors include National Science Foundation.
The ticker symbol of Sol-Gel Technologies is SLGL on NASDAQ.